{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-045886","form_type":"8-K","ticker":"CGTX","cik":"0001455365","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.335018+00:00","generated_at":"2026-05-22T03:51:09.868658+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cognition Therapeutics: oral zervimesine cuts GA lesion growth 28.6% in Phase 2 trial","bullets":["Zervimesine-treated patients had 28.6% slower GA lesion growth rate vs placebo in Phase 2 MAGNIFY study.","At 18 months, mean lesion size was 28.2% smaller for zervimesine group compared to placebo.","Trial concluded early with ~100 of planned 246 enrolled; company focuses resources on Alzheimer's and DLB programs.","Dry AMD is third indication where zervimesine showed efficacy signals; oral pill vs current injectable treatments.","Additional safety, demographic, and visual outcome data still being analyzed; results to be presented at medical meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-045886","json":"https://secwatch.observer/filing/0001104659-25-045886.json","markdown":"https://secwatch.observer/filing/0001104659-25-045886.md","text":"https://secwatch.observer/filing/0001104659-25-045886.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465925045886/0001104659-25-045886-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465925045886/tm2514313d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T03:51:09.868658+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}